Pulmonx Co. (NASDAQ:LUNG) Shares Sold by AQR Capital Management LLC

AQR Capital Management LLC decreased its holdings in Pulmonx Co. (NASDAQ:LUNG) by 81.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,059 shares of the company’s stock after selling 48,671 shares during the period. AQR Capital Management LLC’s holdings in Pulmonx were worth $70,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of the business. Vanguard Group Inc. grew its stake in shares of Pulmonx by 0.6% in the first quarter. Vanguard Group Inc. now owns 2,077,859 shares of the company’s stock worth $19,262,000 after acquiring an additional 11,417 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its stake in shares of Pulmonx by 7.0% during the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,059,018 shares of the company’s stock worth $6,714,000 after purchasing an additional 69,595 shares in the last quarter. Victory Capital Management Inc. grew its stake in shares of Pulmonx by 1.0% during the second quarter. Victory Capital Management Inc. now owns 834,301 shares of the company’s stock worth $5,289,000 after purchasing an additional 8,004 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of Pulmonx by 13.1% during the second quarter. Renaissance Technologies LLC now owns 301,410 shares of the company’s stock worth $1,911,000 after purchasing an additional 34,800 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its stake in shares of Pulmonx by 12.7% during the second quarter. Bank of New York Mellon Corp now owns 157,902 shares of the company’s stock worth $1,001,000 after purchasing an additional 17,740 shares in the last quarter. Institutional investors and hedge funds own 91.04% of the company’s stock.

Insider Transactions at Pulmonx

In other news, CEO Steven S. Williamson acquired 14,245 shares of Pulmonx stock in a transaction that occurred on Tuesday, August 20th. The stock was purchased at an average price of $6.84 per share, for a total transaction of $97,435.80. Following the completion of the transaction, the chief executive officer now directly owns 219,531 shares in the company, valued at approximately $1,501,592.04. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Pulmonx news, insider Geoffrey Beran Rose sold 4,586 shares of the stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $6.70, for a total value of $30,726.20. Following the completion of the transaction, the insider now directly owns 295,433 shares of the company’s stock, valued at approximately $1,979,401.10. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Steven S. Williamson bought 14,245 shares of the company’s stock in a transaction on Tuesday, August 20th. The stock was bought at an average cost of $6.84 per share, with a total value of $97,435.80. Following the completion of the acquisition, the chief executive officer now owns 219,531 shares of the company’s stock, valued at $1,501,592.04. This represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders sold 30,351 shares of company stock worth $231,094. Company insiders own 5.70% of the company’s stock.

Pulmonx Stock Performance

NASDAQ LUNG opened at $6.50 on Friday. The company has a debt-to-equity ratio of 0.37, a current ratio of 8.97 and a quick ratio of 7.92. Pulmonx Co. has a 1 year low of $5.46 and a 1 year high of $14.84. The company has a market capitalization of $252.30 million, a PE ratio of -4.22 and a beta of 0.64. The company has a fifty day moving average of $7.29 and a two-hundred day moving average of $7.38.

Pulmonx (NASDAQ:LUNG) last announced its earnings results on Wednesday, July 31st. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.02. Pulmonx had a negative net margin of 75.56% and a negative return on equity of 50.79%. The business had revenue of $20.78 million during the quarter, compared to the consensus estimate of $20.23 million. As a group, analysts expect that Pulmonx Co. will post -1.64 earnings per share for the current year.

Wall Street Analysts Forecast Growth

LUNG has been the subject of a number of analyst reports. Canaccord Genuity Group boosted their target price on shares of Pulmonx from $15.00 to $16.00 and gave the stock a “buy” rating in a research note on Thursday, August 1st. Wells Fargo & Company lowered their target price on shares of Pulmonx from $14.00 to $10.00 and set an “equal weight” rating for the company in a research note on Thursday, August 1st. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $14.83.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.